NCT00966693 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle
- id
- FG000
- title
- RTD (Cohort 1, Phase 1)
- description
- Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone 40mg \*21 days+ 7 days rest and reevaluation=28 day cycle
- id
- FG001
- title
- RTD (Cohort 2, Phase 1)
- description
- Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle
- id
- FG002
- title
- RTD (Cohort 3, Phase 1)
- description
- Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone 40mg \*21 days+ 7 days rest and reevaluation=28 day cycle
- id
- FG003
- title
- RTD (Cohort 2, Phase 2)
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 2
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 0
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 5
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 16
- type
- Disease Progression
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 9
- group Id
- FG003
- num Subjects
- 49
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 6
- group Id
- FG003
- num Subjects
- 0
- type
- Phase 1 Completed
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 46
- type
- Phase 2 Completed
- achievements
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 6
- group Id
- FG003
- num Subjects
- 26
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 23
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Oral Revlimid 15mg, Thalidomide 100mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle
- id
- FG000
- title
- RTD (Cohort 1, Phase 1)
- description
- Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone 40mg \*21 days+ 7 days rest and reevaluation=28 day cycle
- id
- FG001
- title
- RTD (Cohort 2, Phase 1)
- description
- Oral Revlimid 25mg, Thalidomide 200mg, Dexamethasone 40mg\*21 days+ 7 days rest and reevaluation=28 day cycle
- id
- FG002
- title
- RTD (Cohort 3, Phase 1)
- description
- Oral Revlimid 25mg, Thalidomide 100mg, Dexamethasone 40mg \*21 days+ 7 days rest and reevaluation=28 day cycle
- id
- FG003
- title
- RTD (Cohort 2, Phase 2)
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 2
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 0
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 5
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 1
- group Id
- FG003
- num Subjects
- 16
- type
- Disease Progression
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 9
- group Id
- FG003
- num Subjects
- 49
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 6
- group Id
- FG003
- num Subjects
- 0
- type
- Phase 1 Completed
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 46
- type
- Phase 2 Completed
- achievements
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 6
- group Id
- FG003
- num Subjects
- 26
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 23
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle